Cell Therapy News

Benjamin Schlechter, MD, of Dana-Farber Cancer Institute, discussed a trial-in-progress investigating autologous T-cell antigen coupler T cells targeting HER2 in relapsed or refractory solid tumors in a video interview with Healio.

Chimeric antigen receptor T cells are one of the newest immunotherapy options for multiple myeloma treatment.

In this episode, host Shikha Jain, MD, speaks with Christopher Heery, MD, of Arcellx, Inc. about making the transition from physician to chief medical officer, providing more access and education for clinical trials and more.

“With great power comes great responsibility.”

Several clinicians will be honored at this year’s Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, scheduled for Feb. 15-19 in Orlando.

A phase 3 trial of ciltacabtagene autoleucel for adults with relapsed or refractory multiple myeloma met its primary endpoint, according to the agent’s manufacturer.

A phase 1/phase 2 trial of lisocabtagene maraleucel for adults with advanced chronic lymphocytic leukemia or small lymphocytic lymphoma met its primary endpoint, according to the agent’s manufacturer.

A blood test may predict which patients are predisposed to developing treatment-related neurotoxicity after chimeric antigen receptor T-cell therapy infusion, according to researchers.

A risk model based on low-pass whole-genome sequencing of cell-free DNA predicted which patients are more likely to respond to chimeric antigen receptor T-cell therapy for large B-cell lymphoma, study results showed.

NEW ORLEANS — Lisocabtagene maraleucel can be administered safely in the community setting to patients relapsed or refractory large B-cell lymphoma, according to phase 2 study results.